SCHEMBL23590245

SCHEMBL23590245

CCOc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(F)ccc4n3)c(OC)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.64
▸ SMN1; SMN2 Q16637 4/20 0.64
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ LMNA P02545 2/20 0.56
▸ TP53 P04637 2/20 0.56
▸ PLA2G2A P14555 1/20 0.55
▸ DHODH Q02127 8/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ HPGD P15428 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ POLB P06746 1/20 0.53
▸ CYP1A2 P05177 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ EIF4A1 P60842 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29997066 1.00 KDM4E (0.64) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL23590314 0.92 KDM4E (0.70) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL29997481 0.92 KDM4E (0.70) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL29997602 0.89 DHODH (0.57) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL23590096 0.89 DHODH (0.57) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL23579612 0.88 DHODH (0.57) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL29997055 0.88 DHODH (0.57) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL28891183 0.88 PDE10A (0.57) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL23580627 0.87 DHODH (0.55) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10
SCHEMBL29997421 0.87 DHODH (0.55) KDM4ESMN1; SMN2MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
WO-2023278778-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-01-05 — — WO disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021134042-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD KDM4E 1396/4885SMN1; SMN2 3677/4885MEN1 2373/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH KDM4E 580/4885SMN1; SMN2 3516/4885MEN1 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback